QR Pharma, Inc.
QR Pharma is developing novel drugs to impede the progression of Alzheimer’s, Parkinson’s and other neurodegenerative disorders.
The company is developing Posiphen® which inhibits the synthesis of toxic proteins involved in Alzheimer's and Parkinson's disease. Posiphen is distinct from other drugs in development, because due to its mechanism of action it is effective in a number of neurodegenerative disorders by protecting nerve cells from dying. Posiphen was found to be safe in animals and humans. In AD patients it normalized brain chemistry, making it a promising drug.